194 related articles for article (PubMed ID: 33742364)
1. Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2021 May; 38(5):2750-2756. PubMed ID: 33742364
[No Abstract] [Full Text] [Related]
2. Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Fakhouri W; Sapin C; Holzkaemper T; de la Torre I
Adv Ther; 2021 May; 38(5):2747-2749. PubMed ID: 33742363
[No Abstract] [Full Text] [Related]
3. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
5. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients.
Tóth L; Juhász MF; Szabó L; Abada A; Kiss F; Hegyi P; Farkas N; Nagy G; Helyes Z
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163173
[TBL] [Abstract][Full Text] [Related]
6. [JAK inhibitors in the management of rheumatoid arthritis].
Finckh A
Rev Med Suisse; 2019 Mar; 15(641):528-532. PubMed ID: 30860322
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.].
Yamaoka K
Clin Calcium; 2018; 28(5):678-685. PubMed ID: 29731464
[TBL] [Abstract][Full Text] [Related]
8. [Small molecules treatment in rheumatoid arthritis].
Verdon A; Lauper K
Rev Med Suisse; 2020 Mar; 16(685):477-480. PubMed ID: 32167248
[TBL] [Abstract][Full Text] [Related]
9. [Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].
Kaudewitz D; Lorenz HM
Inn Med (Heidelb); 2023 Oct; 64(10):1005-1012. PubMed ID: 37493758
[TBL] [Abstract][Full Text] [Related]
10. Expanded table: some biologic agents and JAK inhibitors for RA.
Med Lett Drugs Ther; 2018 Jul; 60(1552):e130-e134. PubMed ID: 30044768
[No Abstract] [Full Text] [Related]
11. Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.
Med Lett Drugs Ther; 2019 Nov; 61(1585):183-185. PubMed ID: 31770358
[No Abstract] [Full Text] [Related]
12. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
Kotyla PJ; Islam MA; Engelmann M
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
[TBL] [Abstract][Full Text] [Related]
13. Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?
Avouac J
Joint Bone Spine; 2022 Nov; 89(6):105454. PubMed ID: 35964885
[No Abstract] [Full Text] [Related]
14. A review of upadacitinib in rheumatoid arthritis.
Tanaka Y
Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
[TBL] [Abstract][Full Text] [Related]
15. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
Singh S; Singh S
Int Immunopharmacol; 2020 Sep; 86():106731. PubMed ID: 32590315
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
17. The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?
Tanaka Y
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i1-i3. PubMed ID: 30806705
[No Abstract] [Full Text] [Related]
18. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
19. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2018 Jul; 60(1552):123-128. PubMed ID: 30044766
[No Abstract] [Full Text] [Related]
20. Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.
Meyer A; Wittekind PS; Kotschenreuther K; Schiller J; von Tresckow J; Haak TH; Kofler DM
Ann Rheum Dis; 2021 Dec; 80(12):e196. PubMed ID: 31744827
[No Abstract] [Full Text] [Related]
[Next] [New Search]
